Nov 19, 2020 / 05:35PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Hello, everyone, and welcome to another great session at the Jefferies Virtual Global Healthcare Conference in London. I am doing this fireside chat from London bridges here behind me. And Enrique, my good friend at FibroGen, Chief Executive Officer, Enrique Conterno, is there at the headquarters in San Francisco, hard at work in bringing forward roxadustat.
I just wanted to turn it over to Enrique and maybe take a step back and ask you, an important year, this year, of course, culminated with the potential PDUFA date and then even more important 2021 as you go out and try and execute on a commercial launch.
Questions and Answers:
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity AnalystSo I wanted to start by asking you, what are you most focused on here, as we get into the end of the year, certainly, regulatory discussions is one of them. How are you thinking about the evolution of the regulatory discussions and the results, and how you're thinking about
Trustpilot
